Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy
about
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responsesOverdiagnosis of prostate cancer.Tumor markers in prostate cancer I: blood-based markers.Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancerEarly prostate-specific antigen changes and the diagnosis and prognosis of prostate cancerBiomarkers for the diagnosis of new and recurrent prostate cancer.Molecular biomarkers in prostate cancer.Involvement of urokinase-type plasminogen activator system in cancer: an overview.Biomarkers in prostate cancer: new era and prospective.Assays for prostate cancer : changing the screening paradigm?New Prognostic Markers: The Pathway from Research to Clinical Practice
P2860
Q31161981-37BA771C-199F-4336-B646-0F1980545DDCQ34442512-B3DCA8ED-9596-4003-8312-C4CF81778AC0Q34561148-88F51F91-EC5C-4919-A2A4-B17C84E2EB8FQ35532150-B53C0780-BE09-4DD3-A19A-BEF30E7286E8Q36142693-294E4C2A-691E-492D-B79F-3F5AB37F1601Q36326373-2DE84C21-26CC-48FC-AB5C-50136DA587F1Q36520508-29FC9817-DD5E-43DB-947D-64482B9CEB46Q36607766-28A2A61E-BF4C-43CF-9959-D0105216ECA5Q36610677-ED915F80-AD10-4AD9-BC86-E614D6D3F125Q37422990-5EF47E01-F16F-48D7-85BB-D440D27F7A18Q38052926-EC2030BA-DDF3-4B57-AC7C-72362900DF66Q38088854-A9F2412C-2E33-4F04-A76A-E2630EE5BD20Q38189275-9C4249B1-A6A2-4AF2-AC13-881F2E62EC4EQ38232466-12C907E8-B805-4ECF-B0EE-BA380D419292Q46530327-0CFB317B-BEA2-4481-9445-EA280D447276Q57238952-7A143D8E-167A-423C-A852-84C55C1B0F03
P2860
Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy
description
im Januar 2007 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2007
@uk
name
Free PSA isoforms and intact a ...... nts for prostate cancer biopsy
@en
Free PSA isoforms and intact a ...... nts for prostate cancer biopsy
@nl
type
label
Free PSA isoforms and intact a ...... nts for prostate cancer biopsy
@en
Free PSA isoforms and intact a ...... nts for prostate cancer biopsy
@nl
prefLabel
Free PSA isoforms and intact a ...... nts for prostate cancer biopsy
@en
Free PSA isoforms and intact a ...... nts for prostate cancer biopsy
@nl
P2093
P2860
P356
P1476
Free PSA isoforms and intact a ...... nts for prostate cancer biopsy
@en
P2093
Alexander Haese
Hartwig Huland
James A. Eastham
Michael W. Kattan
Peter T. Scardino
Thomas Steuber
P2860
P304
P356
10.1002/IJC.22427
P577
2007-01-04T00:00:00Z